Physician profile
Connor M Smith
NPI 1447785183
$5,851.72
in general payments reported to CMS, 2019-2025
19 companies · $661 in 2025
The $661 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $958 · 2022: $2,492 · 2023: $982 · 2024: $758 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,401.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,594.95 | 2022-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Alcon Vision LLC | $1,096.78 | 2021-2024 | Clareon, Hydrus Microstent, Argos |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $430.18 | 2021 | |
| Biotissue Holdings INC. | $376.47 | 2023-2025 | |
| Nova Eye, INC. | $362.80 | 2022 | |
| Allergan, INC. | $155.59 | 2021 | |
| Glaukos Corporation | $154.68 | 2021-2025 | Istent Infinite, Idosetr |
| Ocular Therapeutix, INC. | $154.61 | 2022-2024 | Dextenza |
| Abbvie INC. | $120.59 | 2022-2024 | Durysta |
| Novartis Pharmaceuticals Corporation | $89.08 | 2022-2023 | |
| Thea Pharma INC. | $71.42 | 2023-2025 | Iyuzeh |
| Harrow Eye, LLC | $53.69 | 2024-2025 | Vevye |
| Dompe US, INC. | $50.51 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $34.22 | 2024-2025 | Xdemvy |
| Rxsight INC | $28.26 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $24.64 | 2024 | Tecnis Iol |
| Carl Zeiss Meditec USA, INC. | $20.93 | 2023 | Quatera 700 |
| Sun Pharmaceutical Industries INC. | $17.83 | 2024 | |
| Oyster Point Pharma, INC. | $14.49 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connor Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.